Havrix (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure or who seek immunization against the virus.

• Primary prophylaxis for adults and children aged 12 months and older.
• Protection for travelers to regions where hepatitis A is endemic.
• Immunization of laboratory personnel handling hepatitis A virus.
• Use in outbreak settings to control spread of hepatitis A.
• Administration as a two‑dose series, with the second dose given 6–12 months after the first.

Following intramuscular injection, Havrix may cause transient reactions; most are mild and resolve without intervention.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or mild malaise.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis) with symptoms such as difficulty breathing, swelling of the face or throat, and rapid heartbeat.
• Guillain‑Barré syndrome, a rare neurological disorder characterized by muscle weakness.
• Persistent high fever or severe rash.
• Severe joint pain.
• Seizures.

Healthcare providers should assess individual risk factors and medical history before administering Havrix to ensure safe and effective immunization.

• Defer vaccination in persons with known severe allergy to any vaccine component, including aluminium salts.
• Postpone administration in individuals experiencing acute moderate or severe illness.
• Use with caution in patients with compromised immune systems; vaccine may be less effective.
• Discuss potential risks with pregnant or breastfeeding women, as safety data are limited.
• Monitor for signs of anaphylaxis for at least 15 minutes after injection.
• Avoid routine revaccination without documented loss of immunity.

Havrix generally has a low potential for drug interactions, but certain medications and vaccines may influence its safety or effectiveness.

Avoid

• Concurrent administration with live‑attenuated vaccines (e.g., measles, mumps, rubella) should be avoided; separate them by at least 4 weeks.
• Simultaneous use of immunoglobulin products may reduce the immune response to Havrix.

Use with caution

• Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody production; consider timing of vaccination.
• Antipyretics such as acetaminophen or ibuprofen can be used to manage mild post‑vaccination symptoms, but routine prophylactic use may blunt the immune response.
• Blood products or plasma containing hepatitis A antibodies may interfere with vaccine efficacy; schedule vaccination accordingly.